NASDAQ:MITO Stealth BioTherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stealth BioTherapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.30 -0.05 (-3.70 %) (As of 10/1/2020 03:59 PM ET) Add Compare Share Today's Range$1.30Now: $1.30▼$1.3250-Day Range$1.32MA: $1.55▼$1.8952-Week Range$0.90Now: $1.30▼$14.41Volume911 shsAverage Volume310,065 shsMarket Capitalization$45.54 millionP/E Ratio65.03Dividend YieldN/ABeta2.47 ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingStealth BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.17, Stealth BioTherapeutics has a forecasted upside of 523.4% from its current price of $1.31.Amount of Analyst CoverageStealth BioTherapeutics has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesStealth BioTherapeutics has received 72 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStealth BioTherapeutics has received 83 “underperform” votes. (Add your “underperform” vote.)Community SentimentStealth BioTherapeutics has received 53.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote “Outperform” if you believe MITO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStealth BioTherapeutics does not currently pay a dividend.Dividend GrowthStealth BioTherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stealth BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 2.39% of the stock of Stealth BioTherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stealth BioTherapeutics are expected to grow in the coming year, from ($0.09) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stealth BioTherapeutics is 65.53, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Stealth BioTherapeutics is 65.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.31.Price to Book Value per Share RatioStealth BioTherapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MITO Previous Symbol CUSIPN/A CIKN/A Webwww.stealthbt.com Phone617-600-6888Debt Debt-to-Equity RatioN/A Current Ratio1.49 Quick Ratio1.49Price-To-Earnings Trailing P/E Ratio65.03 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.09 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book2.65Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-71,730,000.00 Net MarginsN/A Return on Equity-465.59% Return on Assets-102.96%Miscellaneous Employees73 Outstanding Shares35,030,000Market Cap$45.54 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $1.30 -0.05 (-3.70 %) (As of 10/1/2020 03:59 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MITO News and Ratings via Email Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter. Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions How has Stealth BioTherapeutics' stock been impacted by COVID-19? Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MITO shares have decreased by 18.2% and is now trading at $1.30. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Stealth BioTherapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stealth BioTherapeutics. When is Stealth BioTherapeutics' next earnings date? Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Stealth BioTherapeutics. How were Stealth BioTherapeutics' earnings last quarter? Stealth BioTherapeutics Corp (NASDAQ:MITO) released its earnings results on Thursday, August, 6th. The company reported ($0.02) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.02). View Stealth BioTherapeutics' earnings history. What price target have analysts set for MITO? 6 Wall Street analysts have issued 1 year price targets for Stealth BioTherapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Stealth BioTherapeutics' stock price to reach $8.17 in the next year. This suggests a possible upside of 528.2% from the stock's current price. View analysts' price targets for Stealth BioTherapeutics. Are investors shorting Stealth BioTherapeutics? Stealth BioTherapeutics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 26,100 shares, a decrease of 51.2% from the August 31st total of 53,500 shares. Based on an average trading volume of 156,300 shares, the days-to-cover ratio is presently 0.2 days. View Stealth BioTherapeutics' Short Interest. Who are some of Stealth BioTherapeutics' key competitors? Some companies that are related to Stealth BioTherapeutics include Avadel Pharmaceuticals (AVDL), Heat Biologics (HTBX), Veru (VERU), Avenue Therapeutics (ATXI), Milestone Pharmaceuticals (MIST), OptiNose (OPTN), Mustang Bio (MBIO), BIOFRONTERA AG/ADR (BFRA), NeuBase Therapeutics (NBSE), LifeVantage (LFVN), Five Prime Therapeutics (FPRX), Cerecor (CERC), Theratechnologies (THTX), Theratechnologies (THERF) and Ampio Pharmaceuticals (AMPE). View all competitors. What other stocks do shareholders of Stealth BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), TherapeuticsMD (TXMD), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACB). Who are Stealth BioTherapeutics' key executives? Stealth BioTherapeutics' management team includes the following people: Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 55)Mr. Robert J. Weiskopf, Chief Financial Officer (Age 69)Mr. Henry Hess, Chief Legal CounselDr. Ben R. Bronstein, Chief Medical Officer (Age 70)Dr. Brian D. Blakey, Chief Bus. Officer (Age 58) When did Stealth BioTherapeutics IPO? (MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager. What is Stealth BioTherapeutics' stock symbol? Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO." How do I buy shares of Stealth BioTherapeutics? Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Stealth BioTherapeutics' stock price today? One share of MITO stock can currently be purchased for approximately $1.30. How big of a company is Stealth BioTherapeutics? Stealth BioTherapeutics has a market capitalization of $45.54 million and generates $21.09 million in revenue each year. The company earns $-71,730,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Stealth BioTherapeutics employs 73 workers across the globe. What is Stealth BioTherapeutics' official website? The official website for Stealth BioTherapeutics is www.stealthbt.com. How can I contact Stealth BioTherapeutics? Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected] This page was last updated on 10/1/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
